--- title: 'Industry Daily Summary: What Happened on October 6, 2026' headline: Shionogi to acquire IntraBio for $2 billion, adding rare-disease drug description: Roche and CSL signed large licensing deals. Lilly expanded a research collaboration, and Pacira found a European partner. url: https://thebench.bio/news/industry/2026-10-06 topic: industry date: '2026-10-06' covers: - '2026-10-06' date_published: '2026-10-06T12:05:07Z' date_modified: '2026-10-06T18:51:50Z' sources: 6 publisher: The Bench (thebench.bio) --- # Industry Daily Summary: What Happened on October 6, 2026 **Shionogi to acquire IntraBio for $2 billion, adding rare-disease drug** Roche and CSL signed large licensing deals. Lilly expanded a research collaboration, and Pacira found a European partner. ## Today in brief Shionogi plans to acquire IntraBio for $2 billion, bringing Aqneursa, an approved treatment for two rare neurological disorders, into its portfolio. [1] [2] Roche will pay Alector $100 million upfront for global rights to its preclinical Parkinson’s candidate AL050, with up to $1.17 billion in milestone payments. [3] CSL agreed to pay Alentis $355 million upfront to develop lixudebart for kidney and liver diseases, with up to $1.2 billion more tied to commercial milestones. [4] ## Shionogi to acquire IntraBio and Aqneursa for $2 billion Shionogi announced on October 5 that it would buy IntraBio for $2 billion, gaining global rights to Aqneursa if the deal closes. [1] [2] Aqneursa is approved in the US for Niemann-Pick disease type C and ataxia-telangiectasia, and in Europe for Niemann-Pick disease type C. [1] [2] Shionogi said Aqneursa generated $67.8 million in fiscal 2025 revenue. [2] The company expects the acquisition to close by year-end, subject to regulatory review. [2] ## Roche pays $100 million upfront for Alector’s Parkinson’s candidate Roche licensed global rights to AL050, a preclinical enzyme replacement therapy designed to address GCase deficiency in Parkinson’s disease. [3] Alector will receive $100 million upfront and could earn up to $1.17 billion in development, regulatory and commercial milestones. [3] Genentech will lead development, manufacturing, regulatory work and commercialization across indications. [3] Alector retains its ABC delivery platform, which the company says is designed to help therapies cross the blood-brain barrier. [3] ## CSL backs Alentis’ lixudebart with $355 million upfront CSL and Alentis will develop lixudebart for several kidney and liver diseases under an exclusive collaboration. [4] CSL will pay $355 million upfront and may provide up to $1.2 billion in commercial milestones. [4] Alentis is testing lixudebart in a Phase II trial for ANCA-associated vasculitis with rapidly progressive glomerulonephritis, a severe kidney condition. [4] CSL will fund that program and planned Phase III work, along with Phase II studies in focal segmental glomerulosclerosis and primary sclerosing cholangitis. [4] If the drug reaches the market, Alentis is entitled to 55% of global profits. [4] ## Also worth knowing - Lilly expanded its Gate Bioscience collaboration to cover one new target, with potential milestone payments of up to $870 million and an option to add another target. [5] - Pacira gave Molteni Farmaceutici exclusive rights to commercialize Exparel in the EU and UK. The companies expect the first sale in 2027. [6] ## The day in numbers - **$2 billion**: Shionogi’s agreed purchase price for IntraBio. [1] [2] - **$100 million**: Upfront payment Roche will make to Alector for AL050 rights. [3] - **$355 million**: Upfront payment CSL will make to Alentis for lixudebart collaboration rights. [4] ## Also published - [BridgeBio’s Sum Of The Parts Is Far Too Undervalued To Ignore](), Matt Gamber - [Beyond Market Access: Why healthcare-system understanding is becoming a leadership capability](), pharmaphorum - [“AI biotech” is no longer a useful category for investors](), European Biotechnology - [China deals, Beam lawsuit, MFN models, Nobel winners — a BioCentury podcast](), BioCentury - [Scaling up an innovation culture: a Q&A with argenx’s Karen Massey](), BioCentury - [CSL buys into Alentis’ lead autoimmune program for $355M: Deals Report](), BioCentury - [Building again in rare diseases, Shionogi pays $2B for IntraBio](), BioCentury - [Pharmaceutical Executive Daily: CSL & Alentis Enter $1.6 Billion Global Partnership](), Pharmaceutical Executive - [Shionogi pays $2B to acquire a rare disease startup](), BioPharma Dive - [Roundup: CSL & Alentis Enter Global Partnership, Jiangsu Nhwa Enters Global Licensing Deal with Somnivera](), Pharmaceutical Executive - [Shionogi's diversification continues with $2bn IntraBio buy](), pharmaphorum - [CSL joins forces with Alentis on claudin candidate](), pharmaphorum - [CSL backs Swiss Alentis’ claudin-1 bet with up to $1.6bn deal](), European Biotechnology ## Sources 1. [Shionogi bolsters rare disease portfolio with $2bn IntraBio buyout  ](), Pharmaceutical Technology, 2026-10-06 2. [Shionogi Adds to Its Rare Disease Strategy With $2B IntraBio Acquisition](), MedCity News, 2026-10-05 3. [Alector shares up after sealing $1.27bn Roche Parkinson’s disease license deal](), Pharmaceutical Technology, 2026-10-06 4. [CSL and Alentis ink $1.5bn partnership to progress antifibrotic drug  ](), Pharmaceutical Technology, 2026-10-06 5. [Lilly deepens ties with Gate Bioscience in $870m deal expansion ](), Pharmaceutical Technology, 2026-10-06 6. [Pacira partners with Molteni for Exparel commercialisation](), Pharmaceutical Technology, 2026-10-06 --- The Bench wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: [3]: [4]: [5]: [6]: